9. Halozyme Therapeutics Inc. (NASDAQ:HALO)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is not the usual biotech story, and that is exactly why investors should not ignore it. Instead of depending only on one internal drug, Halozyme has built a royalty-driven platform around its ENHANZE drug-delivery technology, which helps convert certain infused therapies into more convenient subcutaneous formulations. Based on latest market data, Halozyme traded at $67.12, with a market capitalization of about $8.25 billion and a P/E ratio near 23.55. That gives investors profitable biotech exposure with a differentiated royalty and licensing model.
Halozyme’s Q1 2026 results were strong. The company reported total revenue of $377 million, up 42% year over year, while royalty revenue increased 43% to $241 million. Just as important, Halozyme reiterated its 2026 financial guidance and announced a new $1 billion share repurchase program, projecting at least $400 million in buybacks during 2026. That is a major shareholder-return signal, especially in biotech, where many companies are still raising capital instead of buying back stock.
Management said the new buyback reflects “strong cash generation” and confidence in the long-term durability of the business. That is the key phrase for HALO. This is not a moonshot biotech; it is a cash-generating platform company tied to the success of partner products. The risk is partner concentration, regulatory timing, and the need for ENHANZE-enabled products to continue gaining adoption. But for investors looking for biotech exposure with royalties, profitability, and buybacks, Halozyme may be one of the most underrated names in the sector. It is not as loud as oncology or gene therapy, but the financial model is powerful.
Click next to see the following stock...
